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Abstract
Background: Cisplatin is a well-known nephrotoxic antineoplastic drug. Chronic hypokalemic
metabolic alkalosis with hypomagnesemia and hypocalciuria is one of the rare complications
associated with its use.
Case presentation: A 42- year-old woman presented with a 20 year-history of hypokalemic
metabolic alkalosis with hypomagnesemia and hypocalciuria after cisplatin-based chemotherapy for
ovarian cancer. This patient has had chronic muscle aches and fatigue and has had episodic seizure-
like activity and periodic paralysis. Only thirteen other patients with similar electrolyte
abnormalities have been described in the literature. This case has the longest follow-up.
Conclusion: Cisplatin can cause permanent nephrotoxicity, including Gitelman-like syndrome.
This drug should be considered among the possible causes of chronic unexplained electrolyte
disorders.
Background
Cisplatin is the most commonly used antineoplastic agent
for the treatment of solid tumors and is a well-known
cause of nephrotoxicity [1]. In this study we report a case
with chronic hypokalemic metabolic alkalosis with
hypomagnesemia and hypocalciuria 20 years after the ini-
tial treatment with cisplatin therapy. Only three literature
reports have described the association of these electrolyte
abnormalities and cisplatin therapy; our case has the long-
est follow-up. This entity is phenotypically identical to the
autosomal recessive renal tubular disorder described by
Gitelman et al [2].
Case presentation
This 42-year-old woman was diagnosed with ovarian can-
cer in 1986 when she was 23 years old. She had under-
gone a physical examination and laboratory tests during
the prior year with normal results. (These normal labora-
tory results are no longer available.) She was treated with
surgery and 12 courses of cisplatin, adriamycin, and cyclo-
phosphamide. Several months after finishing her chemo-
therapy, she developed right-sided facial and arm
twitching (possible seizures suggested by a neurologist),
carpopedal spasm, and paresthesias in extremities. Head
CT and EEG were normal. Laboratory tests showed
hypokalemia (2.5 mEq/l), hypocalcemia (7.8 mg/dl), and
hypomagnesemia (0.2 mg/dl). From1986 to 2003, she
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noted muscle aches and fatigue. Her plasma K+ levels
ranged from 1.2 to 7.2 mEq/l (n = 44 measurements; 23
values = 3.5 mEq/L), and her Mg++ level ranged from 0.2
to 2.4 mg/dl. (n = 44 measurements; 43 values < 2.1 mEq/
L). She required daily treatment with oral KCL 20–80
mEq, Mg oxide 200–2,400 mg, amiloride 5–20 mg, and
spironolactone 100–200 mg to maintain her electrolytes
in or near the normal range. She was admitted for IV
potassium administration one time in 2002.
In April and August 2003, she had two episodes of
hypokalemic paralysis; plasma K+ levels were 1.2 and 1.6
mEq/l despite taking oral KCL 80 mEq daily. She was then
placed on IV potassium 20 mEq and oral KCL 160 mEq
daily. In August 2003, her Mg++ level was 1.0 mg/dl on
oral Mg oxide 4000 mg daily, and she was started on IV
magnesium sulfate 4 grams weekly.
In January 2004 she presented to our clinic to establish a
new primary care physician. She had muscle aches,
diarrhea, paresthesias, and depression. She denied vomit-
ing and diuretic use. She has had diabetes mellitus for 2
years. There was no family history of any electrolyte disor-
ders. Her medications included magnesium sulfate 4
grams IV weekly, and daily oral KCL 240 mEq, amiloride
5 mg, aldactone 150 mg and avandia 8 mg. Her height was
158 cm; weight 74.1 kg; BMI 29.6; blood pressure 100/80
mm Hg; and pulse 80/min. Her physical examination was
unremarkable. Laboratory data are listed in Table 1. Her
renal ultrasound was normal and had no nephrocalcinois.
Urine screen for thiazide and loop diuretics was negative.
Her laboratory results are consistent with a diagnosis of
Gitelman's syndrome, including hypomagnesemia,
hypokalemia, hypocalciuria and metabolic alkalosis. She
has been seen in our clinic for 18 months with persistent
fatigue and occasional muscle aches. She now takes daily
oral Mg oxide 3,500 mg, KCL 60 mEq, and aldactone 150
mg to maintain serum Mg++ and K +levels in the normal
range.
Discussion
Hypokalemic metabolic alkalosis with hypomagnesemia
and hypocalciuria is a rare complication of cisplatin ther-
apy. We reviewed the worldwide medical literature from
1966 to the present and identified 13 cases with these
electrolyte abnormalities after cisplatin treatment [3-5].
The clinical and laboratory data of these cases and our
case are summarized in 2. The median age of the patients
is 21 yrs old. The cumulative dose of cisplatin ranged from
310 to 1,710 mg/m2. Except for our patient these cases
have not developed symptoms. The mean serum potas-
sium level is 3.4 mEq/l, and the mean serum magnesium
is 1.4 mg/dl. Most patients have had chronic hypomag-
nesemia for at least for 2 years after treatment (range 1–20
years). The mean fractional urinary magnesium excretion
is 6.9%, and the fractional urinary calcium excretion is
0.6%. Seventy percent of patients have a slightly decreased
Table 1: Baseline her laboratory data after cisplatin treatment in 1986 and 2004
June, 1986 January, 2004  Normal range
Serum electrolyte levels
Sodium 133 140 136–145 mEq/l
Potassium 2.5 5.2 3.5–5.1 mEq/l
Chloride 89 105 98–107 mEq/l
Calcium 7.8 9.7 8.8–10.5 mg/dl
Magnesium 0.2 1.3 1.3–2.1 mg/dl
Creatinine - 0.9 0.5–1.2 mg/dl
Serum bicarbonate level 35 26 20–30 mmol/l
Serum pH - 7.5 7.30–7.50
Urine Osmolality 860 300–1,090 mosml/Kg H20
Urine electrolyte excretions
Sodium - 234 40–220 mEq/day
Potassium - 81.3 25–125 mEq/day
Chloride - 221 110–250 mEq/day
Calcium - 35 100–300 mg/day
Magnesium - 57 18–130 mg/day
Urine Ca/Cr ratio - 0.09 0.1–1.06 mmol/mmol
Fractional excretion
Potassium - 33.6%
Magnesium - 8.5%
Calcium - 0.6%
 Potassium values in 2004: 2.9, 3.4, 3.5, 4.6, 4.6, 5.0, 5.1 mEq/L
 Medications: magnesium sulfate 4 grams IV weekly, and daily oral KCL 240 mEq, amiloride 5 mg, and aldactone 150 mg.BMC Nephrology 2006, 7:10 http://www.biomedcentral.com/1471-2369/7/10
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GFR after treatment. The biochemical abnormalities in
these patients resemble Gitelman's syndrome (GS), an
autosomal recessive renal tubular disorder first described
by Gitelman in 1966 [2]. This syndrome is caused by inac-
tivating mutations in the thiazide-sensitive Na-Cl co
transporter (NCCT) gene in the distal convoluted tubule
[2]. The defect in NCCT gene leads to NaCl wasting which
stimulates the renin-angiotensin-aldosterone system,
resulting in hypokalemic metabolic alkalosis [2]. The salt
wasting due to NCCT mutation is high enough to lower
blood pressure and protect patients from hypertension.
However, the RAAS stimulation and the degree of volume
contraction do not stimulate significant renal or systemic
PGE2 production. Therefore, these patients have normal
urinary PGE2 excretion [6]. Renal biopsy in these patients
demonstrates juxtaglomerular hyperplasia, but this find-
ing is non-specific, probably secondary to persistent
sodium depletion and hyperreninnemia [6]. GS causes
salt craving, musculoskeletal complaints, fatigue and diz-
ziness. Progression to renal insufficiency is extremely rare
in GS patients, and only one patient has developed end
stage renal disease [2]. A few patients with GS have devel-
oped chondrocalcinosis probably from chronic hypomag-
nesemia [2].
The mechanisms for hypocalciuria and hypomagnesemia
in GS remain a matter of speculation [2]. Hypocalciuria
may result from membrane hyperpolarization due to
decreased Na+ entrance into the cell, leading to activation
of luminal voltage-gated Ca++  channels and thus
enhanced Ca++reabsorption. Another possibility is
enhanced reabsorption of Ca++in proximal tubular seg-
ments secondary to hypovolemia [2]. Hypomagnesemia
in GS is possibly explained by the observation that a com-
plete block of NCCT by chronic thiazide treatment results
in an increased rate of apoptosis in DCT cells in rats [2].
Therefore, patient with GS may have reduced DCT epithe-
lial surface area, which limits magnesium reabsorption.
Magnesium wasting in the proximal tubule and thick
ascending limb should result in a fractional excretion
greater than 10%. Metabolic alkalosis and hypokalemia
may also have a role in magnesium excretion. Treatment
of GS requires correction of the serum electrolyte abnor-
malities [2]. Most patients with GS require magnesium
supplementation for life. Some also require potassium
salts and/or anti-aldosterone medications to correct and
maintain the serum potassium level [2]. Nonsteroidal
anti-inflammatory drugs are usually not helpful [2]. How-
ever, recent studies demonstrate that COX-2 in the macula
densa modulates renin secretion, and there is one case
report which describes successful treatment of refractory
hypokalemia with a COX-2 inhibitor (rofecoxib) [7].
The mechanism for cisplatin nephrotoxicity remains
uncertain. Cisplatin could cause decreased protein synthe-
sis, membrane peroxidation, mitochondrial dysfunction,
and/or DNA injury and thereby cause tubular injury.
However, a definite relationship between the DNA-bind-
ing and renal cell cytotoxicity has not been established yet
[1]. The morphological studies in humans with cisplatin
nephropathy demonstrate focal tubular necrosis predom-
inantly in the distal convoluted tubule and the collecting
ducts. The glomerulus has no obvious morphologic
changes. Changes in the distal nephron include mito-
Table 2: Laboratory data of Gitelman-like syndrome patients after cisplatin treatment.
Ref. Age/Sex Type of 
Cancer
Cisplatin dose 
(mg/m2)
K+ (mEq/l) Mg++ 
(mg/dl)
FEMg (%) FECa (%) GFR (ml/
m/1.73 m2)
Persist 
(yrs)
1988 (3) 22/M Testicular 459–954¤ 3.4–3.9ψ 1.4 8.9■ 0.9■ 88 2–6¤
1988 (3) 36/M Testicular 459–954¤ 3.4–3.9ψ 1.2 8.9■ 0.9■ 100 2–6¤
1988 (3) 39/M Testicular 459–954¤ 3.4–3.9ψ 1.1 8.9■ 0.9■ 117 2–6¤
1988 (3) 25/M Testicular 459–954¤ 3.4–3.9ψ 1.4 8.9■ 0.9■ 69 2–6¤
1988 (3) 27/M Testicular 459–954¤ 3.4–3.9ψ 1.1 8.9■ 0.9■ 105 2–6¤
1988 (3) 24/M Testicular 459–954¤ 3.4–3.9ψ 1.6 8.9■ 0.9■ 85 2–6¤
1990 (4) 8.5/M Neuroblastoma 720 3.4 1.6 5.5 0.2 85 1.5
1990 (4) 11/F Neuroblastoma 1,710 3.7 1.8 3.4 0.1 102 3.5
1990 (4) 8/M Neuroblastoma 630 3.6 1.2 8.3 0.2 79 1
1991 (5) 13* (4 patients) Neuroblastoma 
Sarcomas
310–1,710¤ 3.2 ♣ 1.4♣ 4.3■ 0.42■ 85■ 1.5*
Our case 42/F Ovarian No data 3.4 1.3 8.5 0.6 80 20
Mean +/- SD 21.0 + 11.1 872 +280 3.4 +0.1 1.4 +0.2 6.9 +2.2 0.6 +0.3 89 +12 3.8 +4.5
 No individual patient data reported.
¤ Use mean value to represent data for calculation of table mean.
ψ Use lowest value to represent data for calculation of table mean.
■  Mean value for all patients from the same study.
♣ Calculated number from figure 1 in ref 5.  Mean value of 1986–2004 data.
* Median value for 12 patients with cisplatin therapy in ref 5.Publish with BioMed Central    and   every 
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chondrial swelling, nuclear pallor, and occasional frank
necrosis [1]. We suggest that cisplatin may cause DNA
injury at the NCCT gene and DCT epithelial apoptosis
which produces Gitelman-like syndrome. Although this
syndrome occurs infrequently, cisplatin causes frequent
renal dysfunction. Hypomagnesemia occurs in 40–100%
of patients and a reduction in GFR occurs in 20–30% of
patients. Solute diuresis and administration of cisplatin in
divided doses or as a continuous infusion reduce nephro-
toxicity [1]. Prompt repletion of magnesium deficits and
administration of supplemental magnesium reduce the
risk of adverse effects from hypomagnesemia. All the case
reports we identified describe patients who probably
received cisplatin in the 1980s. More attention to drug
toxicity has possibly reduced the frequency of this syn-
drome.
Conclusion
This case demonstrates that cisplatin can have permanent
effects on tubular function and can cause significant mor-
bidity. This syndrome should be considered in patients
with unexplained electrolyte abnormalities and a history
of remote therapy for malignancy.
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